Galectin Therapeutics Inc
GALT4.050USD
+0.020+0.50%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
261.11MMarket Cap
LossP/E TTM
More Details of Galectin Therapeutics Inc Company
Galectin Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing therapies to improve the lives of patients with chronic liver disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. The Company’s lead drug, belapectin, is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. The Company's additional development programs are in the treatment of combination immunotherapy for advanced head and neck cancers and other malignancies.
Galectin Therapeutics Inc Info
Ticker SymbolGALT
Company nameGalectin Therapeutics Inc
IPO dateSep 04, 2002
CEOLewis (Joel)
Number of employees15
Security typeOrdinary Share
Fiscal year-endSep 04
AddressSuite 240
CityNORCROSS
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code30071
Phone16786203186
Websitehttps://galectintherapeutics.com/
Ticker SymbolGALT
IPO dateSep 04, 2002
CEOLewis (Joel)
Company Executives of Galectin Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Richard E. Uihlein
Mr. Richard E. Uihlein
Independent Chairman of the Board
Independent Chairman of the Board
10.35M
+0.10%
Mr. Joel Lewis, CPA
Mr. Joel Lewis, CPA
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
921.80K
--
Mr. Kevin D. Freeman
Mr. Kevin D. Freeman
Independent Director
Independent Director
391.58K
-16.15%
Dr. Gilbert S. Omenn, M.D., Ph.D.
Dr. Gilbert S. Omenn, M.D., Ph.D.
Independent Director
Independent Director
82.24K
--
Mr. Jack W. Callicutt, CPA
Mr. Jack W. Callicutt, CPA
Chief Financial Officer
Chief Financial Officer
68.20K
--
Dr. Gilbert F. (Gil) Amelio, M.D., Ph.D.
Dr. Gilbert F. (Gil) Amelio, M.D., Ph.D.
Independent Director
Independent Director
60.61K
--
Dr. Khurram Jamil
Dr. Khurram Jamil
Chief Medical Officer
Chief Medical Officer
38.13K
-36.44%
Dr. Harold H. Shlevin, M.D., Ph.D.
Dr. Harold H. Shlevin, M.D., Ph.D.
Independent Director
Independent Director
11.21K
-26.31%
Dr. Benjamin S. Carson, Sr.
Dr. Benjamin S. Carson, Sr.
Director
Director
--
--
Ms. Elissa J. Schwartz, Ph.D.
Ms. Elissa J. Schwartz, Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Richard E. Uihlein
Mr. Richard E. Uihlein
Independent Chairman of the Board
Independent Chairman of the Board
10.35M
+0.10%
Mr. Joel Lewis, CPA
Mr. Joel Lewis, CPA
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
921.80K
--
Mr. Kevin D. Freeman
Mr. Kevin D. Freeman
Independent Director
Independent Director
391.58K
-16.15%
Dr. Gilbert S. Omenn, M.D., Ph.D.
Dr. Gilbert S. Omenn, M.D., Ph.D.
Independent Director
Independent Director
82.24K
--
Mr. Jack W. Callicutt, CPA
Mr. Jack W. Callicutt, CPA
Chief Financial Officer
Chief Financial Officer
68.20K
--
Dr. Gilbert F. (Gil) Amelio, M.D., Ph.D.
Dr. Gilbert F. (Gil) Amelio, M.D., Ph.D.
Independent Director
Independent Director
60.61K
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Nov 15
Updated: Sat, Nov 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Uihlein (Richard E)
16.05%
10X Fund, L.P.
8.56%
The Vanguard Group, Inc.
3.49%
Osaic Holdings, Inc.
1.90%
Czirr (James C)
1.62%
Other
68.38%
Shareholders
Shareholders
Proportion
Uihlein (Richard E)
16.05%
10X Fund, L.P.
8.56%
The Vanguard Group, Inc.
3.49%
Osaic Holdings, Inc.
1.90%
Czirr (James C)
1.62%
Other
68.38%
Shareholder Types
Shareholders
Proportion
Individual Investor
20.98%
Investment Advisor
11.66%
Corporation
8.56%
Investment Advisor/Hedge Fund
3.13%
Hedge Fund
0.56%
Research Firm
0.55%
Bank and Trust
0.14%
Other
54.41%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
162
10.53M
16.66%
--
2025Q3
163
10.53M
16.66%
-10.00K
2025Q2
165
10.54M
16.95%
+547.90K
2025Q1
161
10.00M
17.03%
-760.02K
2024Q4
155
10.14M
16.54%
+350.43K
2024Q3
135
9.79M
16.30%
+242.19K
2024Q2
125
9.53M
13.05%
+1.91M
2024Q1
106
7.62M
12.37%
-34.09K
2023Q4
107
7.22M
15.34%
-1.84M
2023Q3
118
9.07M
13.34%
+1.79M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Uihlein (Richard E)
10.34M
16.14%
--
--
Feb 28, 2025
10X Fund, L.P.
5.92M
9.24%
--
--
Feb 28, 2025
The Vanguard Group, Inc.
2.18M
3.41%
-7.95K
-0.36%
Jun 30, 2025
Osaic Holdings, Inc.
1.27M
1.98%
+41.97K
+3.43%
Jun 30, 2025
Czirr (James C)
1.09M
1.7%
+323.13K
+42.20%
Jun 06, 2025
Lewis (Joel)
930.30K
1.45%
--
--
Sep 12, 2025
BlackRock Institutional Trust Company, N.A.
868.40K
1.36%
-467.63K
-35.00%
Jun 30, 2025
Geode Capital Management, L.L.C.
666.19K
1.04%
-186.51K
-21.87%
Jun 30, 2025
Eldred (Kary N.)
500.63K
0.78%
+1.00K
+0.20%
Jul 21, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.05%
iShares Russell 2000 Value ETF
0%
iShares Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
Proshares Ultra Russell 2000
0%
iShares Russell 2000 Growth ETF
0%
Global X Russell 2000 ETF
0%
Fidelity Nasdaq Composite Index ETF
0%
ProShares Hedge Replication ETF
0%
iShares Micro-Cap ETF
Proportion0.05%
iShares Russell 2000 Value ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
Fidelity Nasdaq Composite Index ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Galectin Therapeutics Inc?
The top five shareholders of Galectin Therapeutics Inc are:
Uihlein (Richard E) holds 10.34M shares, accounting for 16.14% of the total shares.
10X Fund, L.P. holds 5.92M shares, accounting for 9.24% of the total shares.
The Vanguard Group, Inc. holds 2.18M shares, accounting for 3.41% of the total shares.
Osaic Holdings, Inc. holds 1.27M shares, accounting for 1.98% of the total shares.
Czirr (James C) holds 1.09M shares, accounting for 1.70% of the total shares.
Uihlein (Richard E) holds 10.34M shares, accounting for 16.14% of the total shares.
10X Fund, L.P. holds 5.92M shares, accounting for 9.24% of the total shares.
The Vanguard Group, Inc. holds 2.18M shares, accounting for 3.41% of the total shares.
Osaic Holdings, Inc. holds 1.27M shares, accounting for 1.98% of the total shares.
Czirr (James C) holds 1.09M shares, accounting for 1.70% of the total shares.
What are the top three shareholder types of Galectin Therapeutics Inc?
The top three shareholder types of Galectin Therapeutics Inc are:
Uihlein (Richard E)
10X Fund, L.P.
The Vanguard Group, Inc.
Uihlein (Richard E)
10X Fund, L.P.
The Vanguard Group, Inc.
How many institutions hold shares of Galectin Therapeutics Inc (GALT)?
As of 2025Q4, 162 institutions hold shares of Galectin Therapeutics Inc, with a combined market value of approximately 10.53M, accounting for 16.66% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.00%.
What is the biggest source of revenue for Galectin Therapeutics Inc?
In --, the -- business generated the highest revenue for Galectin Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
